Strides Pharma Science 過去の業績
過去 基準チェック /26
Strides Pharma Scienceの収益は年間平均-29.6%の割合で減少していますが、 Pharmaceuticals業界の収益は年間 増加しています。収益は年間13.3% 6.8%割合で 増加しています。 Strides Pharma Scienceの自己資本利益率は7.8%であり、純利益率は4%です。
主要情報
-29.6%
収益成長率
-29.7%
EPS成長率
Pharmaceuticals 業界の成長 | 17.5% |
収益成長率 | 6.8% |
株主資本利益率 | 7.8% |
ネット・マージン | 4.0% |
前回の決算情報 | 30 Sep 2024 |
最近の業績更新
Recent updates
Strides Pharma Science's (NSE:STAR) Solid Earnings Are Supported By Other Strong Factors
Nov 01Why Investors Shouldn't Be Surprised By Strides Pharma Science Limited's (NSE:STAR) 27% Share Price Surge
Oct 21After Leaping 29% Strides Pharma Science Limited (NSE:STAR) Shares Are Not Flying Under The Radar
Aug 14Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)
Apr 04Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Feb 29Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story
Dec 23We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt
Sep 26Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Jun 08Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 02Is Strides Pharma Science (NSE:STAR) A Risky Investment?
Jun 25Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Dec 21Strides Pharma Science (NSE:STAR) Has Announced That It Will Be Increasing Its Dividend To ₹2.50
Jul 28Estimating The Fair Value Of Strides Pharma Science Limited (NSE:STAR)
Apr 13Should Strides Pharma Science Limited (NSE:STAR) Be Part Of Your Dividend Portfolio?
Mar 04These 4 Measures Indicate That Strides Pharma Science (NSE:STAR) Is Using Debt Extensively
Feb 15Can Mixed Fundamentals Have A Negative Impact on Strides Pharma Science Limited (NSE:STAR) Current Share Price Momentum?
Jan 26The Strides Pharma Science (NSE:STAR) Share Price Is Up 140% And Shareholders Are Boasting About It
Jan 11収支内訳
収支内訳
Strides Pharma Science の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
---|---|---|---|---|
30 Sep 24 | 44,103 | 1,771 | 8,675 | 0 |
30 Jun 24 | 42,086 | -475 | 7,958 | 0 |
31 Mar 24 | 40,511 | -1,248 | 8,034 | 0 |
31 Dec 23 | 39,535 | -1,525 | 7,642 | 0 |
30 Sep 23 | 37,806 | -2,280 | 7,607 | 0 |
30 Jun 23 | 36,783 | -924 | 7,159 | 0 |
31 Mar 23 | 36,884 | -2,212 | 7,686 | 0 |
31 Dec 22 | 35,680 | -1,824 | 7,395 | 0 |
30 Sep 22 | 34,976 | -2,241 | 7,385 | 0 |
30 Jun 22 | 33,220 | -3,909 | 6,692 | 0 |
31 Mar 22 | 30,703 | -4,602 | 6,728 | 0 |
31 Dec 21 | 31,127 | -4,425 | 6,636 | 0 |
30 Sep 21 | 31,504 | -2,830 | 6,120 | 0 |
30 Jun 21 | 32,224 | -543 | 5,817 | 0 |
31 Mar 21 | 33,159 | 2,545 | 5,704 | 0 |
31 Dec 20 | 30,260 | 28 | 5,359 | 0 |
30 Sep 20 | 29,264 | 589 | 5,192 | 0 |
30 Jun 20 | 28,480 | 1,266 | 4,906 | 0 |
31 Mar 20 | 27,520 | 492 | 4,579 | 0 |
31 Dec 19 | 35,828 | 2,859 | 5,872 | 0 |
30 Sep 19 | 34,203 | 2,169 | 5,536 | 0 |
30 Jun 19 | 32,248 | 745 | 5,346 | 0 |
31 Mar 19 | 21,784 | 840 | 3,707 | 0 |
31 Dec 18 | 28,547 | -93 | 5,349 | 0 |
30 Sep 18 | 28,090 | 139 | 5,420 | 0 |
30 Jun 18 | 28,451 | 415 | 4,363 | 0 |
31 Mar 18 | 28,451 | 544 | 5,334 | 0 |
31 Dec 17 | 35,810 | 1,050 | 6,921 | 0 |
30 Sep 17 | 36,593 | 1,124 | 6,931 | 0 |
30 Jun 17 | 35,357 | 1,712 | 6,064 | 0 |
31 Mar 17 | 27,554 | 2,335 | 4,860 | 0 |
31 Dec 16 | 37,237 | 2,840 | 6,984 | 0 |
30 Sep 16 | 36,573 | 2,410 | 6,760 | 0 |
30 Jun 16 | 34,189 | 2,168 | 6,061 | 0 |
31 Mar 16 | 28,622 | 1,317 | 4,026 | 0 |
31 Dec 15 | 24,901 | 1,152 | 5,508 | 0 |
30 Sep 15 | 12,962 | 860 | 3,367 | 0 |
30 Jun 15 | 12,105 | 244 | 3,206 | 0 |
31 Mar 15 | 11,958 | 16 | 1,994 | 0 |
31 Mar 14 | 10,728 | -1,867 | 2,329 | 0 |
質の高い収益: STARは 高品質の収益 を持っています。
利益率の向上: STAR過去に利益を上げました。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: STARの収益は過去 5 年間で年間29.6%減少しました。
成長の加速: STARは昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。
収益対業界: STAR昨年収益を上げたため、昨年の収益成長をPharmaceuticals業界 ( 20.5% ) と比較することは困難です。
株主資本利益率
高いROE: STARの 自己資本利益率 ( 7.8% ) は 低い とみなされます。